Product Name: PIM2 (282-300)
Product Number: PE-01BES85
| Size: | 200 µg | Price: | 48.00 | |
| 1 mg | $US | 96.00 | ||
| 5 mg | 208.00 |
Peptide Name: PIM2 (282-300)
Product Use: Services as a blocking peptide for use with the Pim2-CT rabbit polyclonal antibody (Cat. No.: AB-NK288-2) that is also available from Kinexus. The peptide sequence is located in the C-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LDPWMQTPAEDVPLNPSKGC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2197.5 Da
Peptide Purity Percent after Synthesis and Purification: >80
Product Use: Services as a blocking peptide for use with the Pim2-CT rabbit polyclonal antibody (Cat. No.: AB-NK288-2) that is also available from Kinexus. The peptide sequence is located in the C-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LDPWMQTPAEDVPLNPSKGC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2197.5 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PIM2 pan-specific antibody (Cat. No.: AB-NK288-2)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PIM2 pan-specific antibody (Cat. No.: AB-NK288-2)
Scientific Background: Pim2 is a protein-serine/threonine kinase of the CAMK group and PIM family. The Pim2 protein, along with the related Pim1 and Pim3 proteins, promotes cell survival and proliferation by acting downstream of cytokine and growth factor signalling pathways. It regulates Myc transcription and stabilization by phosphorylation. It also prevents apoptosis by phosphorylating and inactivating the proapoptotic protein Bad. It induces cell survival and proliferation signals via NF-KB cascade and phosphorylation and inhibition of CDKN1A and CDKN1B. Dysregulation of PIM2 can promote cell proliferation and resistance to apoptosis and oncogenesis. The very low frequency of reported somatic mutations in this protein indicates that it may function as a tumour requiring protein (TRP) in many human tumours. Although it is considered as an oncoprotein (OP), it shows a level of bystander mutations typical of most proteins in human cancers. The active form of the protein kinase normally acts to promote tumour cell proliferation. Pim2 is linked to Mantle Cell Lymphomas (LCM), which are non-Hodgkin lymphomas in which is specifically a B-cell lymphoma is also associated the ATM (ataxia telangiectasia mutated) gene.
© Kinexus Bioinformatics Corporation 2017